Facebook will also create a new subsidiary, Calibra, to build a digital wallet for people to store and exchange the currency using apps.Technologyread more
President Donald Trump went after European Central Bank President Mario Draghi on Tuesday for opening the door for more monetary stimulus in Europe, which would weaken the...Marketsread more
Experts expect Facebook's cryptocurrency venture to alleviate some security issues, while introducing new ones.Cybersecurityread more
European Central Bank President Mario Draghi defended the tools that the organization has available.Europe Newsread more
Trump's disruptive trade confrontations have sent shockwaves through the business world, while, insiders say, companies may wonder whether associating with the president could...Politicsread more
According to China's top economic planning body, some local companies are cutting back on their efforts to hire new university graduates.China Economyread more
The chipmaker crush could persist and investors should be selective, but Nvidia looks like a clear buy, one market watcher says.Trading Nationread more
Americans for Prosperity, the political arm of the vast group co-founded by libertarian billionaire Charles Koch, announces it will back the one-term Republican to defend a...Politicsread more
The rollout is part Best Buy's bigger push to be a destination for health tech.Retailread more
Korean Air has provisionally ordered 20 Boeing 787 Dreamliner passenger jets and agreed to lease another 10, the companies said on Tuesday.Aerospace & Defenseread more
German Chancellor Angela Merkel has presided over a tumultuous recent period, which for many, has left Europe on the brink.Commentaryread more
stock bounced back in midday trading Wednesday from lower-than-expected second quarter earnings after the company's management said its generic drug Advair is not being delayed by further FDA-required studies.
After shares of the drug-maker dropped as far as 8 percent in premarket trading, Mylan's CEO Heather Bresch clarified on a call with investors that delaying Advair's launch to 2018 was due to the Food and Drug Administration reorganizing and changing its priorities.
"We see the administration as the barrier, and not the science," Bresch said.
Mylan's second-quarter earnings report missed estimates in what Bresch called "a tough quarter," before adding more optimistically that the company is "managing for the long term." Bresch believes the poor quarterly result was not a "permanent hit" but rather "a deferred one."
The company reported total revenue of $2.96 billion and earnings per share of $1.10, missing estimates of $3.03 billion in revenues and EPS of $1.16, according to analysts surveyed by Thomson Reuters.
Mylan is coping with declining profitability and it adjusted annual earnings forecasts downward. An August 2016 report by the Government Accountability Office found that U.S. generic drug prices have been declining since 2010.
"To say that times are changing would be an understatement," Besch said.
The competitiveness of the market has been a flash point for generic drug-makers, as interim CEO Yitzhak Peterburg blamed his company's recent poor performance on saturation.
"[Teva] experienced … greater competition as a result of an increase in generic drug approvals by the U.S. FDA," Peterburg said in the earnings release. He added that "customer consolidation" hurt sales in the U.S., before saying competition hurt new product launches, some of which were delayed in the recent quarter.
Teva also missed top and bottom line estimates in its most recent earnings report.
Mylan's stock is down more than 17 percent this year while Teva's recent decline puts it about 51 percent lower over the same period.